Search research articles
Contact Us
Filters
Showing results (11-20 of 27) with videos related to
Page
of 3
Sort By:
Clinical Lymphoma, Myeloma & Leukemia
|
February 10, 2015
Myeloablative intravenous pharmacokinetically targeted busulfan plus fludarabine as conditioning for allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphoma
Ernesto Ayala, Javier Figueroa, Janelle Perkins, et al.
Pharmacotherapy
|
March 9, 2026
Real-World Cardiovascular Outcomes of GLP-1 Receptor Agonists in Women With Type 2 Diabetes and Breast Cancer
Cyrille K Cornelio, Kevin Cowart, Janelle Perkins, et al.
Haematologica
|
May 14, 2011
Sirolimus demonstrates activity in the primary therapy of acute graft-versus-host disease without systemic glucocorticoids
Joseph Pidala, Marcie Tomblyn, Taiga Nishihori, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
|
February 9, 2016
Pharmacists' roles in oncology pharmacy services: Results of a global survey
Lisa M Holle, Christy S Harris, Alexandre Chan, et al.
American Journal of Hematology
|
October 5, 2010
Allogeneic hematopoietic cell transplantation for myelofibrosis: a 10-year experience at single institution
Taiga Nishihori, Janelle Perkins, Jongphil Kim, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
February 19, 2014
Pretransplantation 5-azacitidine in high-risk myelodysplastic syndrome
Taiga Nishihori, Janelle Perkins, Asmita Mishra, et al.
Leukemia & Lymphoma
|
March 6, 2020
Reduced-intensity fludarabine/melphalan confers similar survival to busulfan/fludarabine myeloablative regimens for patients with acute myeloid leukemia and myelodysplasia
Elizabeth DiMaggio, Jun-Min Zhou, Ryan Caddell, et al.
Leukemia Research
|
January 22, 2013
Outcome of azacitidine treatment in patients with therapy-related myeloid neoplasms with assessment of prognostic risk stratification models
Vu H Duong, Jeffrey E Lancet, Ezzideen Alrawi, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
January 28, 2010
A randomized phase II trial comparing tacrolimus and mycophenolate mofetil to tacrolimus and methotrexate for acute graft-versus-host disease prophylaxis
Janelle Perkins, Teresa Field, Jongphil Kim, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
March 10, 2011
Fludarabine and pharmacokinetic-targeted busulfan before allografting for adults with acute lymphoid leukemia
Stella Santarone, Joseph Pidala, Marta Di Nicola, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 27) with videos related to
Sort By:
Page
of 3
Clinical Lymphoma, Myeloma & Leukemia
|
February 10, 2015
Myeloablative intravenous pharmacokinetically targeted busulfan plus fludarabine as conditioning for allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphoma
Ernesto Ayala, Javier Figueroa, Janelle Perkins, et al.
Pharmacotherapy
|
March 9, 2026
Real-World Cardiovascular Outcomes of GLP-1 Receptor Agonists in Women With Type 2 Diabetes and Breast Cancer
Cyrille K Cornelio, Kevin Cowart, Janelle Perkins, et al.
Haematologica
|
May 14, 2011
Sirolimus demonstrates activity in the primary therapy of acute graft-versus-host disease without systemic glucocorticoids
Joseph Pidala, Marcie Tomblyn, Taiga Nishihori, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
|
February 9, 2016
Pharmacists' roles in oncology pharmacy services: Results of a global survey
Lisa M Holle, Christy S Harris, Alexandre Chan, et al.
American Journal of Hematology
|
October 5, 2010
Allogeneic hematopoietic cell transplantation for myelofibrosis: a 10-year experience at single institution
Taiga Nishihori, Janelle Perkins, Jongphil Kim, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
February 19, 2014
Pretransplantation 5-azacitidine in high-risk myelodysplastic syndrome
Taiga Nishihori, Janelle Perkins, Asmita Mishra, et al.
Leukemia & Lymphoma
|
March 6, 2020
Reduced-intensity fludarabine/melphalan confers similar survival to busulfan/fludarabine myeloablative regimens for patients with acute myeloid leukemia and myelodysplasia
Elizabeth DiMaggio, Jun-Min Zhou, Ryan Caddell, et al.
Leukemia Research
|
January 22, 2013
Outcome of azacitidine treatment in patients with therapy-related myeloid neoplasms with assessment of prognostic risk stratification models
Vu H Duong, Jeffrey E Lancet, Ezzideen Alrawi, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
January 28, 2010
A randomized phase II trial comparing tacrolimus and mycophenolate mofetil to tacrolimus and methotrexate for acute graft-versus-host disease prophylaxis
Janelle Perkins, Teresa Field, Jongphil Kim, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
March 10, 2011
Fludarabine and pharmacokinetic-targeted busulfan before allografting for adults with acute lymphoid leukemia
Stella Santarone, Joseph Pidala, Marta Di Nicola, et al.
Page
of 3